Related to this topic: Leaflets | Support | Patient+ | UK Guidelines | Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Hepatitis B Vaccination and Hepatitis B Prevention

Introduction

Hepatitis B virus (HBV) is usually spread parenterally or by intimate sexual contact.
This is usually from blood or blood products, whether by intentional transfusion or sharing injection equipment or implements for tattooing.
Exposure to HBV can produce a variety of different states:1

  • 60-65% show subclinical disease and recover fully
  • 20-25% develop acute hepatitis
  • 5-10% become "healthy" carriers i.e. HBsAg +ve after 6 months
  • 5-10% develop chronic hepatitis
  • Those that carry the antigen HBsAg are not at high risk of transmitting the disease, unless they also carry the antigen HBeAg.
  • Carriers of HBeAg are very infectious.

There are two components to preventing Hepatitis B:

  1. Prevention of transmission of the virus
  2. Immunisation

Epidemiology

Prevalence

The incidence of acute Hepatitis B and prevalence of its chronic carrier state varies widely across the globe.
In areas with high endemicity (HBsAg prevalence ≥ 8%; e.g. South East Asia and Africa), more than half of the population becomes infected at some point in their lives.2In countries with low endemicity (HBsAg prevalence ≤ 2%; e.g. North America, Western Europe, Australia), most of the population do not become infected.
Nearly a third of the world population has been infected by hepatitis B at some point, and at least 350 million people are currently chronic carriers of Hepatitis B infection.3
The number of new infections per year was approximately 60,000 in 2004.4
Highest rate of disease occurs in 20-49-year-olds.
Greatest decline has happened among children and adolescents due to routine hepatitis B vaccination.
The estimated frequency of infectious donations entering the blood supply during 1996-2003 was 1.66 per million for Hepatitis B and 0.80 per million for Hepatitis C.5
Considering the different demography of blood donors and those at risk this is likely to be an underestimate of total prevalence.

Incidence

In England and Wales from 1995 to 2000 laboratory data suggested that the annual incidence of HBV infection was 7.4 per 100,000. Antenatal surveillance in London found about ten in 1000 women were HBsAg positive.6

  • Injecting drug use as the commonest cause of transmission.
  • The number of cases attributed to heterosexual contact was fairly stable, whereas the number of cases in homosexual men decreased.
  • Transmission during childhood was rare, but more frequent among South Asians.
  • The incidence in South Asians is relatively high, and their main risk factors are medical treatment overseas and heterosexual contact.
  • A proportion of cases have no reported route of transmission, but it is likely that many are related to injecting drug use.
Risk factors

The main risk groups are:

  • Intravenous drug abusers.
  • Sexual promiscuity, especially amongst homosexual men.
  • People who have received medical treatment, especially blood transfusion in countries that do not screen for HBV are at increased risk.
  • People who have received much blood or especially pooled blood products in former years are at great risk. This is particularly applicable to haemophiliacs.
  • Vigilance is required to keep the disease out of haemodialysis units.
  • HBV can be spread from mother to child during pregnancy, delivery or breast feeding.
    • Most adults infected with the virus recover fully and develop lifelong immunity but babies infected at birth have about a 90% risk of persistent infection.7
    • Children infected between 1 to 10 years have about a 25% chance of persistent infection.
    • In adults the figure is 2 to 10%.
    • About 20% of those infected in infancy or childhood will develop cirrhosis or liver cancer later in life.
  • Immigrants from areas of high prevalence can represent a source of infection.
  • Urine, faeces, saliva, sputum, tears, sweat and vomit do not pose a risk of HIV, Hepatitis B or C unless they are contaminated with blood.
Prevention of transmission

Measures to be taken include:

  • Practise safe sex
  • Avoid sharing intravenous drug paraphernalia
  • Immunise at-risk individuals
  • Wear gloves when exposed to blood or body fluids
  • Clear up blood or body fluids with warm water and detergent
  • Surgical instruments must be disposable or adequately sterilised
  • Safe handling of sharps
  • If there is risk of infected material splashing into the eye, wear goggles
  • Healthcare workers (who are positive for HBeAg) are not permitted to work in areas where they could be a risk to others
  • Transmission of HBV by those who are negative for HBeAg, but positive for HBsAg, has never been shown. However, they are still not allowed to work in haemodialysis units.

More detail is found on the website, "guidance for clinical healthcare workers"

Immunisation

Hepatitis B vaccine is safe and effective but should not be seen as an alternative to a strategy of prevention of transmission.

It is recommended for:

  • Those who may be exposed to blood or blood products through their occupation e.g. health care workers, ambulance crews, carers of high-risk or known patients, and morticians.
  • Travellers who intend to stay for long periods in high prevalence areas.
  • Those considered to be at risk of Hepatitis B through their planned activities, e.g. volunteers undertaking manual work, contact sports, casual sex
  • Young children who may be in close contact with the local population and therefore at risk of cuts and scratches.
  • Travellers with pre-existing medical conditions who may be at higher risk of requiring medical procedures abroad, e.g. pregnancy. (Pregnancy is not a contraindication to immunisation.)
  • Haemophiliacs.
  • Prisoners and prison officers.
  • All pregnant women should be screened for HBV.
  • If positive the baby should receive vaccination soon after birth using an accelerated schedule. This is 95% effective in preventing chronic infection in the baby. The sexual partner and any existing children should also be immunised.

Immunisation schedule
  • The standard course of immunisation involves 3 injections at 0,1 and 6 months.
  • An accelerated course of 0,1 and 2 months is possible
  • Adults who need protection very quickly can have a schedule of 0,7 and 21 days. The vaccine is administered intramuscularly, usually into the deltoid muscle.
  • After an accelerated course a booster at 1 year is recommended.

It can be used in those who are immunocompromised, as with HIV infection, but a higher dose may be required or extra booster injections.
The vaccine should be given into the deltoid region or anterior thigh in babies.
It is less effective if given into the buttock
It is quite possible that a course may give life-long immunity,8 but for heath professionals a booster every 5 years is recommended in those with good antibody response.
Antibody titres should be tested in health professionals 2 to 4 months after the primary course.

  • A titre above 100miu/ml is regarded as adequate.
  • Around 10-15% of adults fail to respond to three doses of vaccine or respond poorly.9
  • Poor responders with titres of 10 to 100miu/ml should have a booster and those with a titre below 10miu/ml should repeat the course.
  • Those over 40 years old, who are obese or who smoke are more likely to fail to respond.
  • Alcoholics are also reported as having lower seroconversion rates, particularly those with advanced liver disease.
  • Patients who are immunosuppressed or on renal dialysis may also respond less well and require larger or more doses of vaccine.
  • Failure to produce any antibody after 2 complete courses should not be seen as necessarily meaning no immunity as immunity to the disease is largely cell-mediated rather than by antibody.
Post-exposure management
  • Post- exposure prophylaxis (PEP) involves giving Hepatitis B vaccine and possibly immunoglobulin too if required.
  • Immunoglobulin is given at a different site and it does not reduce the immune response to the vaccine.
  • If the status of the source is unknown assume infection.
  • PEP may be indicated even if the exposed person has received Hepatitis B vaccine previously.
  • It should be given within 48 hours and certainly no later than 7 days after exposure.
  • The incubation period of the disease is 40 to 160 days.

If the site of exposure is a needle-stick injury, cut or abrasion the site should be immediately washed with soap and water.
It is indicated for babies born to mothers who are chronic carriers of hepatitis B virus or to mothers who have had acute hepatitis B during pregnancy.
More details about PEP can be found in "The Olive Book", "Hepatitis B immunization" and "Guidance for clinical healthcare workers", see websites listed below.

Complications

Adverse reactions to the vaccine are few and usually mild.
There may be some soreness and erythema around the site.
Fatigue, malaise and influenza-like symptoms are rarer.
An association with a Guillain-Barre type syndrome has not been substantiated.

Effective practice

Evidence shows that universal vaccination in countries with a high endemic incidence of Hepatitis B is beneficial.10
The benefit in countries with a low endemic incidence is much less and the most effective management is selective immunization of high risk groups within those countries. Accelerated courses are probably best for drug abusers as they are notoriously difficult to get to complete a course.
Even with immunization it is essential to take all necessary precautions to prevent transmission of the virus.


Document references
  1. Department of Health; The Green Book. Immunisation Against Infectious Disease 2006
  2. Kane M; Global programme for control of hepatitis B infection.; Vaccine. 1995;13 Suppl 1:S47-9. [abstract]
  3. Margolis HS; Hepatitis B virus infection.; Bull World Health Organ. 1998;76 Suppl 2:152-3.
  4. CDC Statistics
  5. Soldan K, Davison K, Dow B; Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003.; Euro Surveill. 2005 Feb;10(2):17-9. [abstract]
  6. Anderson SR, Righarts A, Maguire H; Surveillance of antenatal infections--HIV, hepatitis B, syphilis and rubella susceptibility in London.; Commun Dis Public Health. 2004 Dec;7(4):251-7. [abstract]
  7. DOH.; Children In Need and Hep. B.
  8. No authors listed; Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity.; Lancet. 2000 Feb 12;355(9203):561-5. [abstract]
  9. Hep B Immunisation (DOH Green Book) pdf
  10. Norris S. Mohsen A; Norris S Mohsen A. Hepatitis B Prevention. Clinical Evidence (2005); Hepatitis B (prevention)

Internet and further reading AcknowledgementsEMIS is grateful to Dr Hayley Willacy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 962
Document Version: 2
DocRef: bgp893
Last Updated: 3 Jul 2007
Review Date: 2 Jul 2008






















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site










Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page